scholarly article | Q13442814 |
P356 | DOI | 10.1182/BLOOD-2017-06-791228 |
P698 | PubMed publication ID | 29054911 |
P50 | author | Jesús San Miguel | Q5930658 |
Nizar J Bahlis | Q114442082 | ||
Ludek Pour | Q114442087 | ||
Helgi van de Velde | Q114442097 | ||
Dixie-Lee Esseltine | Q114442105 | ||
Deborah Berg | Q117252347 | ||
Tamás Masszi | Q44908009 | ||
Peter Ganly | Q56754540 | ||
Michele Cavo | Q57233657 | ||
Herve Avet-Loiseau | Q61112732 | ||
S. Vincent Rajkumar | Q61123608 | ||
Shaji K Kumar | Q85960198 | ||
Antonio Palumbo | Q87013105 | ||
Paul G. Richardson | Q87712102 | ||
Philippe Moreau | Q87734443 | ||
Alessandra Di Bacco | Q90126524 | ||
P2093 | author name string | Wee-Joo Chng | |
Christian Langer | |||
Dina Ben-Yehuda | |||
Jianchang Lin | |||
Luisa Viterbo | |||
Arnon Nagler | |||
Andrzej Pluta | |||
P433 | issue | 24 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2610-2618 | |
P577 | publication date | 2017-10-20 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients | |
P478 | volume | 130 |
Q101226332 | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX |
Q91584842 | Hepatitis B virus infection and 1q21 amplification in multiple myeloma |
Q92903027 | Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy |
Q93086330 | Impact of acquired del(17p) in multiple myeloma |
Q91272434 | Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance |
Q90317855 | Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma |
Q89992911 | Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost |
Q64099073 | Management of cardiovascular risk in patients with multiple myeloma |
Q47784917 | Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma |
Q92265584 | Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma |
Q93001945 | Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma |
Q90244255 | Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma |
Search more.